Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4240-4246

  Reidy, Diane Lauren ^a   Vakiani, Efsevia ^a   Fakih, Marwan G ^a   Saif, Muhammad Wasif ^a   Hecht, Joel Randolph ^a   Goodman Davis, Noah ^a   Hollywood, Ellen ^a   Shia, Jinru ^a   Schwartz, Jonathan ^a   Chandrawansa, Kumari ^a   Dontabhaktuni, Aruna ^a   Youssoufian, Hagop ^a   Solit, David B ^a   Saltz, Leonard B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CIXUTUMUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; RAS PROTEIN; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; LEG PAIN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WILD TYPE; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PHOSPHORYLATION; TIME; TREATMENT OUTCOME; UNITED STATES;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77957962308     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.4154     Document Type: Article

References (23)

1. Adams TE, Epa VC, Garrett TP, et al: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093, 2000 (Pubitemid 30598754)
2. Wang Y, Sun Y: Insulin-like growth factor receptor-1 as an anti-cancer target: Blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2:191-207, 2002
3. Moschos SJ, Mantzoros CS: The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 63:317-332, 2002 (Pubitemid 36151524)
4. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518, 2004 (Pubitemid 38868620)
5. Burtrum D, Zhu Z, Lu D, et al: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912-8921, 2003 (Pubitemid 38064071)
6. Wu J, Odman A, Higgins L, et al: In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11:3065-3074, 2005
7. Morgillo F, Kim WY, Kim ES, et al: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13:2795-2803, 2007 (Pubitemid 46788049)
8. Barnes CJ, Ohshiro K, Rayala SK, et al: Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13:4291-4299, 2007 (Pubitemid 47105993)
9. Slomiany MG, Black LA, Kibbey MM, et al: Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 248:269-279, 2007 (Pubitemid 46330562)
10. Brentjen R, Saltz L: Epidermal growth factor receptor blockade and treatment of solid tumor malignancies, in DeVita J, Helman S, Rosenber S (eds): Progress in Oncology. Boston, MA, Jones and Bartlett, 2002, pp 113-128
11. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
12. Saltz L, Rubin M, Hochster H, et al: Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
13. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004 (Pubitemid 41079832)
14. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
16. Thomas RK, Baker AC, Debiasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351, 2007 (Pubitemid 46328493)
17. Fumagalli D, Gavin PG, Taniyama Y, et al: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 10:101, 2010
18. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
19. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007 (Pubitemid 46548951)
20. Freeman DJ, Juan T, Reiner M, et al: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184-190, 2008
21. Peeters M, Siena S, Van Cutsem E, et al: Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115:1544-1554, 2009
22. Tol J, Nagtegaal ID, Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98-99, 2009
23. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007 (Pubitemid 350106711)